BioXcel Therapeutics's earnings per share without non-recurring items for the
three
months ended in Dec. 2023 was $-0.75.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for BioXcel Therapeutics's EPS without NRI or its related term are showing as below:
BTAI'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -147.4 Med: -43.6 Max: -16.6
Current: -16.6
BTAI's 3-Year EPS without NRI Growth Rate is ranked worse than 72.55% of 1297
companies
in the Biotechnology industry
Industry Median: 4.5
vs BTAI: -16.60
BioXcel Therapeutics's EPS (Diluted) for the
three
months ended in Dec. 2023 was $-0.75.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.14.
BioXcel Therapeutics's EPS (Basic) for the
three
months ended in Dec. 2023 was $-0.75.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.14.
BioXcel Therapeutics EPS without NRI Historical Data
The historical data trend for BioXcel Therapeutics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
BioXcel Therapeutics Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EPS without NRI
-2.06
-3.79
-4.05
-5.92
-6.01
BioXcel Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EPS without NRI
-1.95
-1.84
-1.83
-1.58
-0.75
Competitive Comparison
For the Biotechnology subindustry, BioXcel Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics PE Ratio without NRI Distribution
For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's PE Ratio without NRI falls into.
BioXcel Therapeutics EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (NAS:BTAI) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
BioXcel Therapeutics EPS without NRI Related Terms
Thank you for viewing the detailed overview of BioXcel Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
BioXcel Therapeutics (BioXcel Therapeutics) Business Description
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BTAI has been successfully added to your 